Fig. 4.
Methylation of HIC1 was an independent predictor of poorer survival. LSCC patients without HIC1 methylation (n = 74) had a median survival of 4.40 (range, 0.04 to 16.21) as compared to a median survival of 1.02 years (range, 0.044 to 2.88) for patients (n = 5) with HIC1 methylation